BioneerCorp
KOSDAQ:064550
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioneerCorp
Accounts Receivables
BioneerCorp
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioneerCorp
KOSDAQ:064550
|
Accounts Receivables
₩12.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
|
Celltrion Inc
KRX:068270
|
Accounts Receivables
₩2T
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Accounts Receivables
₩1.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
91%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Accounts Receivables
₩80.8m
|
CAGR 3-Years
332%
|
CAGR 5-Years
141%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accounts Receivables
₩37.2B
|
CAGR 3-Years
64%
|
CAGR 5-Years
81%
|
CAGR 10-Years
57%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Accounts Receivables
₩59.1B
|
CAGR 3-Years
2 371%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
BioneerCorp
Glance View
BIONEER Corp. engages in the manufacture and sale of biotechnological products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2005-12-29. The firm mainly focuses on the development of deoxyribonucleic acid (DNA) reagents, molecular diagnostic kits and other services, such as DNA and ribonucleic acid (RNA) amplification products, Oligo synthesis and reagents, gene synthesis services, gene expressions, protein expressions and purifications, genomics services, human diagnostics kits, veterinary diagnostics kits and others. The company also provides DNA devices, including DNA extraction, amplification and quantitative analysis devices and other DNA diagnostic devices, and supplies for tests and others. In addition, it provides equipment and supplies used for biotechnology research. The firm operates its business within domestic market and in overseas markets, including America, China, Japan, India, Africa and others.
See Also
What is BioneerCorp's Accounts Receivables?
Accounts Receivables
12.8B
KRW
Based on the financial report for Dec 31, 2025, BioneerCorp's Accounts Receivables amounts to 12.8B KRW.
What is BioneerCorp's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
0%
Over the last year, the Accounts Receivables growth was -9%. The average annual Accounts Receivables growth rates for BioneerCorp have been -2% over the past three years , 2% over the past five years .
